Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Nabriva Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Nabriva Therapeutics Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Nabriva Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Nabriva Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Nabriva Therapeutics Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Nabriva Therapeutics Plc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Nabriva Therapeutics Raises USD120 Million in Series B Financing 11
Private Equity 13
Ally Bridge Invests in Nabriva Therapeutics 13
Licensing Agreements 14
Sinovant Sciences Enters into Licensing Agreement with Nabriva 14
Equity Offering 15
Nabriva Therapeutics Raises USD50 Million in Public Offering of Shares 15
Nabriva Therapeutics Raises USD80 Million in Public Offering of Shares 17
Nabriva Therapeutics Raises USD25 Million in Rights Offering of Shares 19
Nabriva Therapeutics Raises USD106.1 Million in IPO of ADS 21
Acquisition 23
Nabriva Therapeutics Acquires Zavante Therapeutics 23
Nabriva Therapeutics Plc – Key Competitors 24
Nabriva Therapeutics Plc – Key Employees 25
Nabriva Therapeutics Plc – Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Recent Developments 27
Financial Announcements 27
Aug 09, 2018: Nabriva Therapeutics reports second quarter 2018 financial results and recent corporate highlights 27
May 08, 2018: Nabriva Therapeutics Reports First Quarter 2018 Financial Results and Recent Corporate Highlights 29
Mar 16, 2018: Nabriva Therapeutics Announces 2017 Financial Results 30
Nov 09, 2017: Nabriva Therapeutics Reports Third Quarter 2017 Financial Results and Recent Corporate Highlights 32
Aug 07, 2017: Nabriva Therapeutics Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights 34
May 10, 2017: Nabriva Therapeutics Reports First Quarter 2017 Financial Results 36
Mar 24, 2017: Nabriva Therapeutics Provides Business and Development Update and Reports 2016 Financial Results 37
Corporate Communications 38
Mar 21, 2018: Nabriva Therapeutics Names Jennifer Schranz As Chief Medical Officer 38
Dec 13, 2017: Nabriva Therapeutics Added to NASDAQ Biotechnology Index 39
Aug 31, 2017: Nabriva Therapeutics Announces Resignation of Elyse Seltzer, M.D. 40
Jul 11, 2017: Nabriva Therapeutics Appoints Francesco Maria Lavino as Chief Commercial Officer 41
Jun 26, 2017: Nabriva Therapeutics Appoints Carrie Bourdow and Colin Broom to the Board 42
Product News 43
10/04/2017: Zavante Therapeutics Presents Additional Clinical And Microbiologic Data From ZOLYD Phase 2/3 Trial At ID Week 2017 43
09/28/2017: Nabriva Therapeutics to Present Lefamulin Data at ID Week 2017 45
09/20/2017: Zavante Therapeutics To Present ZOLYD Data From Pivotal ZEUS Study At ID Week 2017 47
06/05/2017: Zavante Therapeutics Reports ZOLYD Broad Spectrum Activity and Synergy With Multiple Antibiotics; in vitro Studies Presented at ASM Microbe 2017 Meeting 49
04/05/2017: Zavante Therapeutics’ ZOLYD Met Primary Endpoint in Pivotal ZEUS Study for Treatment of Complicated Urinary Tract Infections 50
Clinical Trials 52
May 31, 2018: Nabriva Therapeutics to Present Lefamulin Data at ASM Microbe 52
May 29, 2018: Nabriva Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference 54
May 21, 2018: Nabriva Therapeutics Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial of Oral Lefamulin for the Treatment of Community-Acquired Bacterial Pneumonia 55
May 21, 2018: Zavante Therapeutics to Present Fosfomycin For Injection Data At ASM Microbe 2018 Meeting 57
Apr 13, 2018: Nabriva Therapeutics to Present Data at ECCMID Demonstrating Potential of Lefamulin for Patients with Community-acquired Bacterial Pneumonia 59
Dec 04, 2017: Nabriva Therapeutics Announces Completion of Enrollment in LEAP 2, a Phase 3 Clinical Trial Evaluating Oral Lefamulin for the Treatment of Community-Acquired Bacterial Pneumonia in Adults 61
Oct 25, 2017: Nabriva Therapeutics to Present at the Stifel 2017 Healthcare Conference 62
Sep 20, 2017: Nabriva Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference 63
Sep 18, 2017: Nabriva Therapeutics Announces Positive Topline Results from Global, Phase 3 Clinical Trial Evaluating IV and Oral Lefamulin for the Treatment of Community-Acquired Bacterial Pneumonia 64
Jun 05, 2017: Nabriva Therapeutics Announces Webcast of Analyst & Investor Day on June 19, 2017 66
Jun 05, 2017: Zavante Therapeutics Presents Positive Results From NIH-Sponsored ZOLYD Phase 1 Trial At ASM Microbe 2017 Meeting 67
Jun 02, 2017: Nabriva Therapeutics to present data at ASM Microbe supporting ongoing Phase 3 clinical development program for lefamulin 68
May 17, 2017: Zavante Therapeutics to Present ZOLYD Data at ASM Microbe 2017 Meeting 69
Apr 13, 2017: Nabriva Therapeutics to present data at ECCMID supporting ongoing Phase 3 clinical development program for lefamulin 71
Apr 11, 2017: Nabriva Therapeutics Announces Enrollment Completion for LEAP 1, a Phase 3 Clinical Trial Evaluating Lefamulin in Community-Acquired Bacterial Pneumonia 73
Feb 02, 2017: Nabriva Therapeutics Confirms No Sample Size Adjustment Required for LEAP 1 Phase 3 Trial of Lefamulin in Community Acquired Bacterial Pneumonia 74
Jan 19, 2017: Zavante Therapeutics Reports Completion Of Patient Treatment In The ZEUS Study Of ZTI-01 (fosfomycin for injection) For The Treatment Of Complicated Urinary Tract Infections 75
Appendix 76
Methodology 76
About GlobalData 76
Contact Us 76
Disclaimer 76
Nabriva Therapeutics Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Nabriva Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Nabriva Therapeutics Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Nabriva Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Nabriva Therapeutics Plc, Deals By Therapy Area, 2012 to YTD 2018 9
Nabriva Therapeutics Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Nabriva Therapeutics Raises USD120 Million in Series B Financing 11
Ally Bridge Invests in Nabriva Therapeutics 13
Sinovant Sciences Enters into Licensing Agreement with Nabriva 14
Nabriva Therapeutics Raises USD50 Million in Public Offering of Shares 15
Nabriva Therapeutics Raises USD80 Million in Public Offering of Shares 17
Nabriva Therapeutics Raises USD25 Million in Rights Offering of Shares 19
Nabriva Therapeutics Raises USD106.1 Million in IPO of ADS 21
Nabriva Therapeutics Acquires Zavante Therapeutics 23
Nabriva Therapeutics Plc, Key Competitors 24
Nabriva Therapeutics Plc, Key Employees 25
Nabriva Therapeutics Plc, Subsidiaries 26
List of Figures
Nabriva Therapeutics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Nabriva Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Nabriva Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Nabriva Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Nabriva Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Nabriva Therapeutics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Nabriva Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Nabriva Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
【免責事項】
http://www.globalresearch.jp/disclaimer